单价H7N9流感疫苗联合AS03佐剂与季节性流感疫苗序贯或同时接种的安全性和免疫原性:一项随机临床试验
该开放标签随机对照试验在149名健康成人中比较AS03佐剂H7N9灭活疫苗与四价季节性流感疫苗同时或序贯接种的免疫原性和安全性。结果显示,无论同时还是序贯接种,H7N9疫苗均诱导适度免疫应答,但180天后应答下降;四价疫苗在各组免疫原性相似,同时接种组反应原性略高,未发生与疫苗相关的严重不良事件。
要点
- H7N9 IIV第2剂后3周,组1(同时接种)HAI抗体保护率51%(95%CI 37%-65%),组2(序贯接种)为40%(95%CI 25%-56%)。
- 同一时间点MN抗体保护率组1为84%(95%CI 72%-93%),组2为74%(95%CI 60%-86%)。
- 至第2剂后180天,两组HAI或MN抗体保护率均低;四价疫苗各株应答在各组相似,同时接种组反应原性略高。
核心结论
- AS03佐剂H7N9灭活疫苗无论与四价季节性流感疫苗同时还是序贯接种,均具有适度免疫原性,但180天后应答下降。
- 四价季节性流感疫苗无论采用何种接种程序均具有免疫原性。
研究设计与样本
- 开放标签、随机、对照试验,纳入健康成人,比较AS03佐剂2017年灭活甲型H7N9流感疫苗(H7N9 IIV)与四价季节性流感疫苗(IIV4)同时或序贯接种。
- 组1同时接种H7N9 IIV和IIV4,3周后接种H7N9 IIV;组2仅接种IIV4,然后以3周间隔接种两剂H7N9 IIV;组3接种一剂IIV4。
- 采用血凝抑制(HAI)和微量中和(MN)试验检测几何平均滴度和血清保护(滴度≥1:40),并监测安全性;共149名受试者。
主要发现
- H7N9 IIV第2剂后3周,HAI血清保护率组1为51%(95%CI 37%-65%),组2为40%(95%CI 25%-56%)。
- 同一时间点MN血清保护率组1为84%(95%CI 72%-93%),组2为74%(95%CI 60%-86%)。
- H7N9 IIV第2剂后180天,组1和组2的HAI或MN血清保护率均低。
- IIV4接种后3周,各组对IIV4各株的HAI和MN应答相似。
- 单次接种后征集性局部和全身反应相似,同时接种H7N9和IIV4者反应原性略多;未发生与接种研究产品相关的严重不良事件或就医不良事件。
关键数值与推荐
- 血清保护定义为HAI或MN滴度≥1:40。
- H7N9 IIV第2剂后3周HAI血清保护率:组1 51%(95%CI 37%-65%),组2 40%(95%CI 25%-56%)。
- H7N9 IIV第2剂后3周MN血清保护率:组1 84%(95%CI 72%-93%),组2 74%(95%CI 60%-86%)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Influenza A/H7N9 viruses have pandemic potential. METHODS: We conducted an open-label, randomized, controlled trial of AS03-adjuvanted 2017 inactivated influenza A/H7N9 vaccine (H7N9 IIV) in healthy adults. Group 1 received H7N9 IIV and seasonal quadrivalent influenza vaccine (IIV4) simultaneously, followed by H7N9 IIV three weeks later. Group 2 received IIV4 alone and then two doses of H7N9 IIV at three-week intervals. Group 3 received one dose of IIV4. We used hemagglutination inhibition (HAI) and microneutralization (MN) assays to measure geometric mean titers and seroprotection (≥1:40 titer) to vaccine strains and monitored for safety. RESULTS: Among 149 subjects, seroprotection by HAI three weeks after H7N9 IIV dose 2 was 51% (95 %CI 37%-65%) for Group 1 and 40% (95 %CI 25%-56%) for Group 2. Seroprotection by MN at the same timepoint was 84% (95 %CI 72%-93%) for Group 1 and 74% (95 %CI 60%-86%) for Group 2. By 180 days after H7N9 IIV dose 2, seroprotection by HAI or MN was low for Groups 1 and 2. Responses measured by HAI and MN against each IIV4 strain three weeks after IIV4 vaccination were similar in all groups. Solicited local and systemic reactions were similar after a single vaccination, while those receiving simultaneous H7N9 and IIV4 had slightly more reactogenicity. There were no serious adverse events or medically-attended adverse events related to study product receipt. CONCLUSIONS: Adjuvanted H7N9 IIV was modestly immunogenic whether administered simultaneously or sequentially with IIV4, though responses declined by 180 days. IIV4 was immunogenic regardless of schedule. CLINICAL TRIALS REGISTRATION: NCT03318315.
引用
- Ortiz JR, Spearman PW, Goepfert PA, et al. Safety and immunogenicity of monovalent H7N9 influenza vaccine with AS03 adjuvant given sequentially or simultaneously with a seasonal influenza vaccine: A randomized clinical trial. Vaccine. 2022. PMID: 35465983. doi:10.1016/j.vaccine.2022.03.055
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。